Why Mind Medicine Stock Is Skyrocketing Today

Source The Motley Fool

Mind Medicine (NASDAQ: MNMD) stock is seeing impressive gains Friday. The company's share price was up 16.9% as of 3:15 p.m. ET and had been up as much as 20.7% on the day earlier in the session.

Mind Medicine's valuation is surging following Robert F. Kennedy Jr.'s approval as health and human services (HHS) secretary in yesterday's Senate vote. Kennedy has previously voiced support for psychedelics as therapeutic treatments.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

Mind Medicine stock soars on RFK Jr.'s HHS confirmation

In a 52-to-48 vote yesterday, RJK Jr. was approved as the U.S.'s new HHS secretary. Among President Donald Trump's cabinet nominations, Kennedy's confirmation vote was viewed as one of the more likely to fall through. But he was confirmed for the cabinet role with nearly unanimous Republican support. Sen. Mitch McConnell from Kentucky was the only Republican to vote against Kennedy.

RFK Jr. has previously said that he supports the use of psychedelic drugs as therapeutic treatments in some instances. With the new HHS secretary being a supporter of Mind Medicine's core competency, it's possible that the biotech company will have an easier time bringing its products to the market.

What's next for Mind Medicine?

Political dynamics appear to be shifting in Mind Medicine's favor. The clinical-stage biopharmaceutical company has yet to record any revenue, but it's making progress with testing phases for its core treatments.

On Dec. 16, the company published a press release announcing that its phase 3 study for lysergide D-tartrate (LSD) as a treatment for generalized anxiety disorder was scheduled to kick off in the first half of 2025. Then on Jan. 16, the company announced that the first patient in the clinical test had been dosed. Roughly 250 patients are expected to be tested in the trial, and the results are likely to have a big impact on Mind Medicine's share price.

Should you invest $1,000 in Mind Medicine (MindMed) right now?

Before you buy stock in Mind Medicine (MindMed), consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mind Medicine (MindMed) wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $829,128!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of February 7, 2025

Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
Author  TradingKey
6 hours ago
As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
placeholder
Gold Price Forecast: Gold Holds Key $3,850 Support, US October Retail Sales May Drive Rebound Toward $4,000As of the Asian session on Tuesday (November 17), gold (XAUUSD) maintained a weak rebound intraday today after recent continuous declines to a nearly one-year low, edging up 0.2% during t
Author  TradingKey
6 hours ago
As of the Asian session on Tuesday (November 17), gold (XAUUSD) maintained a weak rebound intraday today after recent continuous declines to a nearly one-year low, edging up 0.2% during t
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 17, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
Author  Mitrade
10 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 17, 2026. Read on for the details.
placeholder
Australian Dollar declines below 0.6750 after RBA minutes, US Retail Sales data in focusThe AUD/USD pair trades with mild losses around 0.6730 during the early Asian session on Tuesday.
Author  FXStreet
14 hours ago
The AUD/USD pair trades with mild losses around 0.6730 during the early Asian session on Tuesday.
placeholder
Bitcoin Plunges 13% in a Week as Market Retreats to $60,000 LevelBitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
Author  TradingKey
Yesterday 10: 05
Bitcoin plunged 13% over the past seven days as bullish defense lines crumbled in succession, officially kicking off the battle to defend the $60,000 mark.On November 16, following a viol
goTop
quote